News
August 17, 2023
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development...
May 17, 2023
Tara Franks, Chief Operating Officer of TD2, recognized as a 2023 Phoenix Titan 100
SCOTTSDALE, ARIZONA, UNITED STATES, May 17, 2023 / EINPresswire.com/ -- Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, Chief Operating Officer of Translational Drug Development (TD2), as a 2023 Phoenix Titan 100. The Titan 100...
April 11, 2023
TD2 to Highlight the Development of a Novel Metabolomic Cancer Model at the AACR Annual Meeting 2023
SCOTTSDALE, ARIZONA, UNITED STATES, April 11, 2023/EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their preclinical development of a novel Diet-Induced Obesity Model for antitumor, proteomic, and metabolomic studies at the...
October 05, 2022
TD2 Announces Dr. Alan Miller as New Chief Medical Officer
The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth. SCOTTSDALE, ARIZONA, UNITED STATES, October 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the addition of Dr. Alan...
August 25, 2022
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
August 09, 2022
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
May 12, 2022
Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial
HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in...
April 05, 2022
TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting
SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research...
March 30, 2022
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it...
October 14, 2021
TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials
Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions. Rave CTMS and eTMF are...
Events
September 26, 2023
Fierce Clinical Summit
Hilton Philadelphia at Penn’s Landing | Philadelphia, PA
